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transplantation. Partial thrombosis is more common than com-
plete thrombosis. Despite careful screening at evaluation, a num-
ber of patients are still found with previously unrecognized
thrombosis per-operatively. The objective is to recanalize the
portal vein or, if recanalization is not achievable, to prevent the
extension of the thrombus so that a splanchnic vein can be used
as the inﬂow vessel to restore physiological blood ﬂow to the
allograft. Anticoagulation during waiting time and transjugular
intrahepatic portosystemic shunt (TIPS) are two options to
achieve these goals. TIPS may achieve recanalization in patients
with complete portal vein thrombosis. However, a marked
impairment in liver function, which is a characteristic feature of
most candidates for transplantation, may be a contraindication
for TIPS. Importantly, the MELD score is artiﬁcially increased by
the administration of vitamin K antagonists due to prolonged
INR. When patency of the portal vein and/or superior mesenteric
vein is not achieved, only non-anatomical techniques (renoportal
anastomosis or cavoportal hemitransposition) can be performed.
These techniques, which do not fully reverse portal hypertension,
are associated with higher morbidity and mortality risks. Multi-
visceral transplantation including the liver and small bowel
needs to be evaluated. In the absence of prothrombotic states
that may persist after transplantation, there is no evidence that
pre-transplant portal vein thrombosis justiﬁes long term antico-
agulation post-transplantation, provided portal ﬂow has been
restored through conventional end-to-end portal anastomosis.
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jugular intrahepatic portosystemic shunt.Restoring both portal and arterial blood ﬂow to the allograft is a
necessary condition for liver transplantation to be successful.
While arterial blood ﬂow is the only source of oxygen supply to
the donor’s biliary tract, portal blood ﬂow ensures most of the
oxygen supply to the parenchyma, which is crucial for recovery
of liver function. In addition, restoration of the portal ﬂow
through the allograft rapidly reverses portal hypertension, which
is a major source of complications in cirrhosis.
Portal vein thrombosis (PVT) is increasingly recognized in cir-
rhotic patients, especially in candidates for transplantation.
Indeed, these patients have detailed imaging at evaluation and
thereafter, repeated imaging, which offers the opportunity to rec-
ognize thrombosis occurring while on the waiting list. PVT is
most often asymptomatic in patients with advanced cirrhosis
so that diagnosis is based on systematic imaging. The proper
impact of PVT on the natural history of cirrhosis remains unclear
[1]. There is no evidence that PVT leads to further deterioration in
liver function in advanced cirrhosis. However, independent of
clinical course and disease severity, PVT may be a source of tech-
nical difﬁculties in the particular setting of transplantation, with
a negative impact on the outcome. Occasionally, it may represent
a deﬁnitive contraindication for transplantation. This review
examines issues concerning the incidence, predisposing factors,
and management of PVT in candidates for liver transplantation.
We also discuss issues concerning the impact of PVT on the out-
come and surgical alternatives in patients with extensive
thrombosis.Incidence, mechanisms, and consequences of portal vein
thrombosis in cirrhosis
The prevalence of PVT in cirrhotic patients at evaluation or at the
time of transplantation varies from 5% to 26% (Table 1) [2–11].
The majority of patients have partial thrombosis. The relatively
high prevalence of PVT in candidates for transplantation could
be related to more advanced disease. However, the prevalence
of PVT in candidates for transplantation seems to be similar to
that found in cirrhotic patients who were not necessarily
evaluated for transplantation [3,12,13]. Even in the most recent
series, a signiﬁcant proportion of patients with PVT at the time
of surgery were previously unrecognized (up to 50%) [4,9]. This
ﬁnding could be related to either false negatives on imaging at
evaluation or to thrombosis occurring while on the waiting list.
The rate of false negatives may obviously vary according to12 vol. 57 j 203–212
Table 1. Prevalence of portal vein thrombosis in patients undergoing evaluation for transplantation or transplantation.
Author, [Ref.] Year Patients Prevalence of PVT* (%) Partial/complete PVT (%) Timing of diagnosis of PVT
Gayowski et al., [11] 1996 88 26 - Transplantation
Yerdel et al., [10] 2000 779 8 - Transplantation
Manzanet et al., [5] 2001 391 16 12/4 Transplantation
Molmenti et al., [6] 2002 1546 5 - Transplantation
Llado et al., [2] 2005 355 12 - Transplantation
Francoz et al., [4] 2005 251 8 7/1 Evaluation†
Tao et al., [7] 2009 465 9 - Transplantation
Dumortier et al., [9] 2010 468 8 7/1 Transplantation
Englesbe et al., [3] 2010 574 5 0/5** Transplantation
Ravaioli et al., [8] 2011 889 10 6/4 Transplantation
⁄PVT, portal vein thrombosis.
⁄⁄Patients with partial thrombosis were not considered.
In this series, the incidence of de novo thrombosis from evaluation to transplantation was 7.4% for an average waiting time of 12 months.
Frontiers in Liver Transplantationdifferent imaging protocols. However, even in patients undergo-
ing
systematic ultrasound during waiting time at close intervals
(every 3–4 months for instance), the rate of previously unrecog-
nized thrombosis remains relatively high [9], emphasizing the
need to improve screening. Few data have been reported on the
incidence of thrombosis occurring while on the waiting list. In
one study, the incidence was found to be of 7% for a mean waiting
time of 12 months [4].
In non-cirrhotic patients, PVT is most often related to pro-
thrombotic states (myeloproliferative neoplasms and/or inher-
ited coagulation disorders) [14]. By contrast, in cirrhotic
patients, portal hemodynamics seems to be the main factor
leading to thrombosis. The characteristic parenchymal changes
of cirrhosis as well as changes in vasoreactivity result in
increased intrahepatic vascular resistance and reduced portal
ﬂow [15,16]. Paradoxically, low platelet count seems to be an
independent predisposing factor for PVT in cirrhosis [4,16].
The inverse correlation between platelet count and PVT may
be due to the fact that reduced portal ﬂow resulting from portal
hypertension outweighs a possibly ‘‘protective’’ effect of low
platelet count against thrombosis [17]. Advanced cirrhosis is
also characterized by a decrease in coagulation factors, which
is theoretically viewed as ‘‘protective’’ against thrombosis. How-
ever, evidence shows that low coagulation factors do not
exclude the occurrence of splanchnic and systemic thrombosis.
Indeed, both pro and anticoagulant factors are decreased in cir-
rhosis, resulting in a compensated hemostatic balance [18,19].
Patients with cirrhotic and non-cirrhotic liver diseases, for
instance, may be at higher risk of venous thromboembolism
compared to controls [20]. Molecular studies have shown that
some thrombophilic genotypes, including factor V Leiden muta-
tion, may be more frequent in cirrhotic patients with PVT com-
pared to cirrhotic patients without thrombosis [12,13]. The role
of methylene tetrahydrofolate reductase mutation has not been
clearly demonstrated. However, even in patients with compen-
sated cirrhosis, it remains difﬁcult to detect an underlying pro-
thrombotic condition due to the non-speciﬁc decrease in
coagulation factors and inhibitors [14]. The potential role of
chronic inﬂammatory state resulting from bacterial products204 Journal of Hepatology 201translocation in the pathogenesis of PVT needs to be further
investigated.
Tumor invasion involving the branches and/or the trunk of
the portal vein is a possible source of portal vein obstruction
in patients with hepatocellular carcinoma (HCC). While, cruoric
thrombosis may not preclude transplantation in patients with
HCC [21], macroscopic vascular invasion by the tumor is a
deﬁnitive contraindication. Therefore, in candidates for trans-
plantation with HCC and portal vein obstruction, a clear distinc-
tion between tumor invasion and thrombosis should be made.
High alpha fetoprotein level, endovascular obstruction adjacent
to the tumor, enlargement of the vessel by the endovascular
material and enhancement of the intravascular material at the
arterial phase on imaging are consistent with tumor invasion
[22]. Contrast-enhanced ultrasonography (US) may also help
distinguish malignant invasion from cruoric thrombosis by
showing an arterial signal within the endoluminal material [23].
The impact of PVT on the outcome of cirrhosis is an unresolved
issue. As discussed above, PVT generally occurs in patients with
advanced cirrhosis and severe portal hypertension. As a result,
the issue of whether PVT is a mere marker of advanced disease
or an event actually contributing to further deterioration in liver
function has not been clearly addressed. Evidence that PVT is an
independent prognostic factor in cirrhosis is still lacking.Management of portal vein thrombosis in candidates for
transplantation
The main objective in the management of PVT in candidates for
transplantation is to achieve at least partial recanalization so that
portal ﬂow to the graft can be restored through conventional
end-to-end portal vein anastomosis. When recanalization is not
achievable, the objective is to prevent further extension of the
thrombus during waiting time, especially to the superior mesen-
teric vein. Indeed, when neither the portal vein nor the superior
mesenteric vein can be used, alternative (non-anatomical) tech-
niques to restore portal ﬂow are associatedwith increasedmorbid-
ity and mortality. Careful screening for PVT at evaluation is crucial
to achieve these goals. Repeated imaging during waiting time is
also needed in order to detect thrombosis (Fig. 1A and B) [4].2 vol. 57 j 203–212
AB
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Both Doppler ultrasonography (US) and multiphasic (arterial
and portal) helical computed tomography (CT) can be recom-
mended at evaluation. Doppler US is highly accurate at detect-
ing thrombosis involving the trunk of the portal vein and in
intrahepatic branches. It provides additional information con-
cerning portal ﬂow and its direction. CT helps better assess
the superior mesenteric vein, spontaneous portosystemic
shunts, renal veins, and the inferior vena cava. Magnetic reso-
nance imaging (MRI) is an alternative to CT in patients with
impaired renal function. However, the deﬁnition is lower than
that of CT, especially in patients with tense ascites [24]. System-
atic Doppler US may be recommended every 3 months during
waiting time, whenever possible.
In patients with PVT, three approaches can be considered: sys-
temic anticoagulation, transjugular intrahepatic portosystemic
shunt (TIPS), and endovascular procedures with ﬁbrinolysis.Fig. 1. Helical computed tomography showing patent portal vein (A, white
arrow) in a candidate for liver transplantation with alcohol-related cirrhosis
at evaluation. Six months later, follow up computed tomography in the same
patient shows the occurrence of de novo portal vein thrombosis. The
thrombus is partial and involves the trunk of the portal vein (B, white arrow).Anticoagulation
Whereas the usefulness of anticoagulation in acute PVT without
underlying liver disease has been clearly documented [25], only
few studies have been conducted in patients with cirrhosis
(Table 2). In theory, anticoagulation in cirrhosis is justiﬁed by
the preserved balance between pro and anticoagulant factors,
even when coagulation factors are decreased. Table 2 shows
that most series of cirrhotic patients treated by anticoagulation
only had partial thrombosis with persistent, although reduced,
portal ﬂow. Various protocols have been used including low
molecular weight heparin and vitamin K antagonists (VKA). As
shown in Table 2, complete recanalization may be achieved in
40–75% of patients while less than 10% experience an extension
of the thrombus [4,26,27]. The rate of recanalization is signiﬁ-
cantly higher in patients receiving anticoagulation than in con-
trol patients who do not [4]. In those with complete thrombosis,
recanalization seems uncommon but anticoagulation may pre-
vent the extension of the thrombus [28]. Interestingly, anticoag-
ulation does not have a signiﬁcant impact on blood loss and
duration of transplant surgery [4].
There is no consensus on which anticoagulation is best sui-
ted in this context. Low molecular weight heparin (LMWH)
can be used until transplantation. While LMWH may be safe
and as effective as VKA, it is less practical for the patients, with
the need for subcutaneous injections. However, one advantage
of LMWH is that it does not interfere with the MELD score.
Another option is to start VKA with a target INR of 2–3 [4]. On
the one hand, VKA can be given orally and anticoagulation can be
reversed rapidly at the time of transplantation by the administra-
tion of fresh frozen plasma. On the other hand, monitoring may
be difﬁcult in patients with a baseline increase in INR [29]. In a
patient with a baseline INR over 2 for instance, it may be difﬁcult
to determine if a given dose of VKA ensures adequate anticoagu-
lation. It may also be difﬁcult to determine the optimal INR target
for dose adjustment.
Thrombin inhibitors and inhibitors of activated factor X such
as dabigatran and rivaroxaban could be an attractive option
[30]. These newer agents offer the advantage of oral administra-
tion, the absence of laboratory monitoring, and a mechanism of
action which is independent of antithrombin [29]. However, no
data are available yet in cirrhotic patients who could be at risk
of excessive anticoagulation.Journal of Hepatology 201Even though there is no evidence that anticoagulation
increases the risk of variceal bleeding [4,26], it is recommended
to check for varices, initiate and/or optimize beta blockers or per-
form elastic band ligation before starting anticoagulation.
It has been proposed recently that systematic anticoagulant
therapy could help prevent PVT in advanced cirrhosis. Preliminary
data suggest that enoxaparin for prolonged periods (12 months)
could decrease signiﬁcantly the incidence of de novo PVT com-
pared to a placebo, without relevant side effects [31]. These results
have to be validated.
Transjugular intrahepatic portosystemic shunt
The objective of TIPS is to recanalize the portal vein and, subse-
quently, prevent rethrombosis by restoring portal ﬂow through a
low resistance shunt. It clearly appears that the feasibility of TIPS
varies according to the extent of thrombosis. Technical failuremay
be related to the absence of visibility of intrahepatic branches of
the portal vein, transformation of the portal vein into a ﬁbrous
cord and extension of the thrombus to the superior mesenteric
vein. However, TIPS may be feasible in some patients with caver-
noma [32–35]. In the largest series, feasibility ranged from 70% to
100% (Table 3) [32,33,36]. Applicability could be lower and pro-
spective studies giving the proportion of patients in whom TIPS
was not considered due to PVT are needed. Ideally, TIPS insertion
and recanalization might be associated with disrupture of the
thrombus and mechanical thrombectomy. However, there are
only few data on the comparison between feasibility and throm-
bectomy [36,37]. Even if TIPS insertion is most often associated2 vol. 57 j 203–212 205
Table 2. Efﬁcacy and safety of anticoagulation for portal vein thrombosis in cirrhotic patients.
Author, [Ref.] Year Patients Partial/complete thrombus Treatment Complete 
recanalization (%)
Extension Treatment-related 
events
Francoz et al., [4] 2005 19 18/1 Nadroparin 
or VKA*
42 5% 0
Senzolo et al., [27] 2009 26 - LMW 
heparin**
50 - 2†
Amitrano et al., [26] 2010 28 23/5 Enoxaparin 75 7% 0
⁄VKA, vitamin K antagonist.
⁄⁄LMW, low molecular weight.
One episode of heparin-induced thrombocytopenia and one episode of non-variceal bleeding.
Table 3. Feasibility, efﬁcacy, and safety of TIPS in cirrhotic patients with portal vein thrombosis.
Author, [Ref.] Year Patients Complete 
thrombosis 
(%)
Feasibility
(%)
Encephalopathy
(%)
TIPS dysfunction
(%)
Long term 
anticoagulation 
(%)
Transplantation
(%)
Bauer et al., [79] 2006 9 44 100 - 22 11 22
Senzolo et al., [36] 2006 28 82 73 4 26 53 11
Han et al., [32] 2011 57 38 75 25 20 100 -
Luca et al., [37] 2011 70 - 100 27 38 0 21
Frontiers in Liver Transplantationwith thrombectomy, residual thrombosis of the superior mesen-
teric vein is possible. There is no evidence to recommend either
TIPS or anticoagulation as the ﬁrst line option when both options
are available. TIPS should only be considered in experienced
centers.
In the perspective of transplantation, the crucial point is that
TIPS should not be inserted distally into the portal vein trunk and
superior mesenteric vein as it would compromise transplant pro-
cedure [38].
In the long term, the rate of dysfunction and/or rethrombosis
ranges from 21% to 38% with the need for revision in some
patients [32,33,36,37]. About 20–30% develop encephalopathy.
Independent of PVT, the rate of dysfunction is signiﬁcantly lower
with covered stents compared to bare stents [39]. However, there
is no evidence that covered stents are superior in candidates for
transplantation who stay on the waiting list for a relatively lim-
ited period of time.
The main limitation of TIPS in this context is that most can-
didates for transplantation have advanced cirrhosis with a high
MELD score. TIPS is generally contraindicated in patients with a
high MELD score due to further deterioration in liver function
and a high mortality risk. A threshold MELD score value of 18
has been proposed as the upper limit for considering TIPS
[40]. Previous episodes of spontaneous encephalopathy also rep-
resent a contraindication. Whether patients with a patent TIPS
should be placed on long term anticoagulation has been a mat-
ter of debate. Several studies have shown that long term
patency can be achieved without anticoagulation [32,33,37].
Therefore, except in patients with documented prothrombotic
state, systematic anticoagulation should not be recommended.
Overall, anticoagulation and TIPS are two possible options
without evidence for superiority of one against the other. The
pros and cons of each option are summarized in Table 4.206 Journal of Hepatology 201Endovascular procedures and ﬁbrinolysis
The results of systemic or in situ thrombolysis in non-cirrhotic
patients with acute PVT have been dismal with a low rate of
recanalization and a high incidence of major bleeding [14,41].
Experience in cirrhotic patients with PVT is very limited [42]. A
ﬁrst concern is that it is relatively uncommon to identify recent
PVT in cirrhotic patients. A second concern is that transhepatic
approach may be more difﬁcult in patients with portal hyperten-
sion. There is no data to support this option.Impact of portal vein thrombosis on organ allocation: is
priority justiﬁed?
Because the increasing demand in liver transplantation markedly
exceeds organ supply, a major concern in the transplant commu-
nity has been to optimize equity in allograft allocation. Most
Western countries have adopted a ‘‘sickest ﬁrst’’ allocation policy
and the MELD score represents the reference tool to determine
priority [43,44]. Unfortunately, the MELD score is not a universal
prognostic score in cirrhosis. It is inaccurate at predicting out-
come in a number of conditions such as refractory ascites and
hepatopulmonary syndrome. Such conditions are generally con-
sidered MELD exceptions [45]. Whether PVT is an independent
risk factor or is a surrogate marker of severity in cirrhosis is still
debated [3]. Several studies have shown that PVT could increase
post-transplant mortality and morbidity [3,10,46]. By contrast,
for a given MELD score, evidence that patients with PVT are at
higher risk of waiting list mortality compared to patients without
thrombosis is lacking. A recent study based on the Scientiﬁc Reg-
istry of Transplant Recipients data in the United States has shown
that PVT was not an independent predictor of waiting list mortal-2 vol. 57 j 203–212
Table 4. The pros and cons of anticoagulation and TIPS in the treatment of portal vein thrombosis in cirrhotic patients awaiting transplantation.
Anticoagulation TIPS
Pro Non-invasive and safe option
Documented efficacy in partial thrombosis
Anticoagulation is easy to reverse at the time of transplant 
VKA monitoring and dose adjustment difficult in patients with a 
procedure
Feasibility in 70-80% of patients
Recanalization possible in patients with complete portal vein 
thrombosis
Low rate of dysfunction
Con
baseline increase in INR
Potential risk of bleeding
Low rate of recanalization in patients with complete thrombosis
TIPS may compromise transplantation in case of misplacement
TIPS contraindicated in patients with high MELD score
Risk of encephalopathy
Table 5. Surgical options in patients with splanchnic vein thrombosis according to the extent of thrombosis.
Extent of thrombosis at transplantation Surgical options Anatomical Reverses portal 
hypertension
Partial portal vein thrombosis Thrombectomy and end-to-end portal anastomosis yes yes
Complete portal vein thrombosis Thrombectomy and end-to-end portal anastomosis yes yes
Jump graft between the SMV* and donor’s portal vein no yes
Complete thrombosis involving the SMV Renoportal anastomosis (end-to-end anastomosis 
between the left portal vein and donor’s portal vein ± 
vascular graft)
no no**
Cavoportal hemitransposition ± IVC† calibration no no
Combined multivisceral transplantation including the 
liver small bowel and pancreas
yes yes‡
⁄SMV, superior mesenteric vein.
⁄⁄Except in patients with patent surgical splenorenal shunt.
IVC, inferior vena cava.
Reversion may not always be complete.
JOURNAL OF HEPATOLOGYity [47]. However, this study has not classiﬁed the extension of
thrombosis.
Practically, PVT is not considered a MELD exception and
patients with PVT do not receive extra points for organ allocation
[45,48,49].
An important concern is that the MELD score which relies on
creatinine, bilirubin and INR is inappropriate in patients receiving
VKA [44]. VKA artiﬁcially increases INR. As an example, in a
patient with creatinine, bilirubin and INR values of 100 lmol/L
(1.14 mg/dl), 100 lmol/L (5.8 mg/dl), and 1.0, respectively, the
MELD score is 14. If INR rises to 2.5 due to the administration
of VKA, there is a 71% increase in the MELD score (MELD score
of 24). In this situation, the MELD score would overestimate the
risk of early mortality and would over prioritize patients receiv-
ing VKA.
In order to overcome this difﬁculty, the MELD score should be
calculated before starting VKA. Thereafter, there are two possible
ways to update the MELD score. The ﬁrst way is to use the so
called MELD-XI score which only relies on creatinine and biliru-
bin with the following equation: MELD-XI = 5.11  Ln(bilirubin
[mg/dl]) + 11.76  Ln(creatinine [mg/dL]) + 9.44 [50]. The MELD-
XI is normalized to the same scale as the MELD score. However,
it can be argued that the MELD-XI does not take into account
baseline coagulation, which is an important prognostic factor.
Another way is to use factor V (which is not affected by VKA)
instead of INR. Indeed, there is a strong but non-linear correlation
between INR and factor V. INR can be estimated from factor V
according to the following equation: INR = (factor V [% of nor-
mal]/94.9)0.81 [51]. The accuracy of the MELD-XI and that of
the change from INR to factor V need further evaluations.Journal of Hepatology 201Impact on liver transplant procedure
The technical options for transplantation vary according to the
patency of the portal vein and that of other splanchnic veins.
When full patency of the portal vein has been achieved, whatever
anticoagulation or TIPS have been used pre-transplantation,
‘‘conventional’’ end-to-end portal anastomosis is the ﬁrst line
option. When full patency has not been achieved, the technical
option depends upon the extent of PVT (i.e., partial or complete)
and the patency of splenic and mesenteric veins. The different
surgical options are presented in Table 5.
Patients with partial portal vein thrombosis
In patients who still have partial PVT at the time of transplanta-
tion, the objective is to optimize portal blood ﬂow to the graft.
Removal of the clot within the portal vein by eversion thrombec-
tomy or thrombendvenectomy (i.e., removal of the clot and the
attached intimal layer of the vein) is the reference technique
[6,8,9,52,53]. Following complete dissection, the portal vein
should be maintained open with tonsil clamps and the clot should
be circumferentially freed and removed while the venous wall is
everted [9]. The maneuver may be extended to the splenic and/
or superior mesenteric vein when needed. Before completing the
anastomosis, portal ﬂow is veriﬁed by removing the clamps and
the portal vein is ﬂushed. Eventually, an end-to-end portal anasto-
mosis is performed as close as possible to the origin of the native
portal vein [6]. Interposition of a vascular graft should be avoided
whenever possible [8]. If, while the clot has been removed, portal
ﬂow remains insufﬁcient, ligation of the collateral circulation2 vol. 57 j 203–212 207
Fig. 2. Helical computed tomography showing complete obstruction of the
main trunk of portal vein (white arrow) by a cruoric thrombus in a patient
with alcoholic cirrhosis.
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(especially splenorenal shunts) should be performed. However,
there is no evidence that collateral circulation should be systemat-
ically ligated.
In most series, patients who underwent transplantation with
thrombectomy received low molecular weight heparin within
the ﬁrst months following transplantation. Long term administra-
tion of anticoagulation was not considered even though, in some
series, patients were systematically placed on aspirin [9], an
option which is not speciﬁc to PVT.
Patients with complete thrombosis limited to the portal vein
Thrombectomy or thrombendvenectomy may be possible even in
some patients with complete PVT [6,9] (Fig. 2). According to the
technique described above, portal ﬂow should be restored, allow-
ing end-to-end portal anastomosis. However, when the native
portal vein corresponds to a ﬁbrotic remnant and/or when the
thrombus involves the splenomesenteric conﬂuence, it may be
impossible to restore adequate blood ﬂow into the portal vein.
In this situation, the distal mesenteric vein can be used as the
inﬂow vessel. Portal ﬂow to the allograft is restored through the
interposition of an iliac donor vein as a jump graft between the
distal superior mesenteric vein and the donor portal vein
[6,53,54]. The extra anatomic jump graft is placed anterior to
the pancreas and posterior to the stomach [54]. Again, if the blood
ﬂow to the donor’s portal vein is not optimal, large portosystemic
shunts may be ligated. Endovascular radiological procedures con-
sisting in the identiﬁcation and embolization of large shunts with
coils have been proposed as an alternative to surgical ligation [55].
Eventually, it has been suggested that the donor’s portal vein may
be successfully implanted onto collateral vessels [52].
Portal vein arterialization consists in improving portal ﬂow by
creating an anastomosis between an arterial branch and the
donor’s portal vein [56]. Arterialization may be performed using
the recipient’s hepatic artery through a side-to-side anastomosis,
an iliac graft between the aorta and the portal vein or an arterial
branch of the coeliac axis [56,57]. Only case reports or small ser-
ies have been published, showing that calibrated arterialization
may help restore portal ﬂow without overt portal hypertension.
However, aneurysmal dilatation of the portal vein has been
reported in the long term [56].
Systematic use of extracorporeal veno-venous bypass in
patients with PVT has been advocated in order to prevent the
hemodynamic consequences of inferior vena cava and portal vein
clamping during the procedure [6]. However, patients who
already have portal vein obstruction and who, as a consequence,
have developed large and/or multiple collateral vessels are unli-
kely to present signiﬁcant hemodynamic changes following
clamping of the remnant splanchnic vessels. No data support sys-
tematic use of veno-venous bypass.
Patients with diffuse splanchnic vein thrombosis
When complete thrombosis extends to the portal vein, the sple-
nic vein and the superior mesenteric vein distally, no splanchnic
vessel can be used as physiological inﬂow vessels. Patients with
extensive thrombosis frequently have complex portosystemic
derivations with cavernoma (Fig. 3). Two alternative techniques
using systemic veins as the inﬂow vessels have been proposed:
cavoportal hemitransposition and reno-portal anastomosis [58–
60].208 Journal of Hepatology 201In cavoportal hemitransposition, the inﬂow comes from the
inferior vena cava which is anastomosed to the donor’s portal
vein in an end-to-end, end-to-side or side-to-end fashion
[58,59]. The suprarenal vena cava, over the anastomosis, can be
calibrated to direct preferentially the blood ﬂow to the portal
vein. However, complete obstruction of the inferior vena cava
may increase the risk of congestion with impaired renal function
and lower limb edema.
In renoportal anastomosis, the portal inﬂow comes from the
left renal vein which is directly anastomosed to the donor’s portal
vein in and end-to-end fashion [58,61–63] (Fig. 4). Alternatively,
the interposition of an iliac vein graft from the donormay be used.
Renoportal anastomosis is best suited in patients who had sur-
gical splenorenal shunt, provided it remains patent [64]. Indeed,
the splenorenal shunt, which should not be occluded, results in
a decompression of the splanchnic system with a beneﬁcial
impact on portal hypertension [59]. In patients without previous
splenorenal shunt, the choice between cavoportal hemitransposi-
tion and renoportal anastomosis depends upon individual ana-
tomical considerations and technical skills. Importantly, it must
be noted that, in contrast to anatomical procedures, these non-
anatomical procedures where the portal inﬂow comes from a sys-
temic vein do not fully reverse portal hypertension (with the
exception of patients with a previous surgical splenorenal shunt).
As these non-anatomical options do not reverse portal hyper-
tension, multivisceral transplantation including the liver, small
bowel and pancreas has been proposed in diffuse thrombosis
and life-threatening upper digestive bleeding [65]. The organs
are procured en bloc and the blood ﬂow is re-established through
the donor’s celiac trunk anastomosed to the recipient’s infrarenal
aorta. In theory, for anatomical reasons, multivisceral transplan-
tation including the liver and the small bowel represents the best
option in patients with diffuse splanchnic vein thrombosis as it
restores physiological portal blood ﬂow and reverses portal
hypertension. However, it is a complex procedure and the high
rate of rejection of the small bowel is a limiting factor [66]. In a
context of drastic organ shortage, more data are needed on the
individual survival beneﬁt of this approach.
Impact of portal vein thrombosis on living donor liver
transplantation
Living donor transplantation may be even more difﬁcult than
deceased donor transplantation in patients with PVT for several
reasons. A partial graft procured from a living donor only has a2 vol. 57 j 203–212
Fig. 3. Helical computed tomography showing organized portal vein throm-
bosis with cavernoma (white arrow) in a cirrhotic patient at evaluation. The
trunk of the portal vein which is no longer visible is surrounded by numerous
collateral vessels.
Fig. 4. Helical computed tomography showing patent left renoportal anasto-
mosis (white arrow) 2 years after liver transplantation in a patient with
complete obstruction of the portal and mesenteric veins at the time of the
procedure.
JOURNAL OF HEPATOLOGYvery short length of portal vein. The recipient’s portal vein must
be long enough to complete the anastomosis with the graft
[67,68]. Finally, procurement of additional vessels for complex
reconstruction or jump graft is limited. Indeed, morbidity in the
donor should be as low as possible.
Several reports, however, have shown that PVT is not an abso-
lute contraindication for living donor transplantation [67–69].
This is especially important since, as well as in recipients of a
deceased donor, some recipients in living donor transplantation
may be found with previously undetected thrombosis at the time
of the procedure [67,68]. In previous series, most patients had
partial thrombosis that could be removed by eversion thrombec-
tomy allowing end-to-end portal anastomosis. When patency
could not be achieved and/or the native portal vein was not long
enough, an iliac or jugular vein procured in the recipient could be
used for reconstruction [68]. Finally, some patients had caval
transposition with dismal results [68]. In general, patients with
extensive splanchnic vein thrombosis should not be oriented to
living donor transplantation due to more technical difﬁculties
and a high mortality rate [70].Post-transplant outcome
Several studies comparing cirrhotic patients with and without PVT
did not ﬁnd signiﬁcant differences in terms of post-transplant sur-
vival [6–9]. However, the largest series that has been reported so far
suggests that, independent of the MELD score, pre-transplant PVT
may be associated with a 50% increase in 1-year mortality risk
post-transplant [47]. The results of this study also suggest that after
the ﬁrst year, PVT no longer impacts negatively on the outcome
[47]. Mortality varies according to the extension of the thrombus
and the surgical procedure. In patients with PVT, when end-to-
end portal anastomosis can be performed, whatever PVT is partial
or complete, the results are similar to those in patients without
PVT. One and 5-year survival ranges from 84% to 86% and from
65% to 80%, respectively [5,6,8,9,53]. In contrast, alternative surgi-
cal techniques usedwhenend-to-endportal anastomosis is not fea-
sible are associated with a worse prognosis. For instance, early
post-operative mortality risk in renoportal anastomosis and cavo-
portal hemitransposition is of about 25% [58]. One and 5-year sur-
vival rate following these techniques may be of only 60% and 38%,
respectively [59]. Not only does PVT increase post-transplant mor-Journal of Hepatology 201tality, it also increases morbidity. Post-transplant morbidity
includes gastrointestinal bleeding due to persistent portal hyper-
tension in about 30% [58,59,62,63], ascites, renal dysfunction [58]
and sepsis [8,58,59,62,63]. Prophylaxis against post-transplant var-
iceal bleeding should be applied including beta-blockers and/or
endoscopic band ligation. Thrombotic events have also been
reported including thrombosis of the anastomosis as well as pul-
monary embolism and hepatic artery thrombosis [58,59]. Patients
with underlying prothrombotic states are likely to be at increased
risk for these events.
Transplant survival beneﬁt, namely, the net difference
between survival with medical management alone and survival
with transplantation emerged as an attractive tool to identify
patients whowould justify transplantation in the context of organ
shortage and those who do not [71]. In patients with a low MELD
score, transplantation may be even more hazardous than remain-
ing on the waiting list due to the intrinsic mortality andmorbidity
of the procedure. A recent study has shown that the threshold cor-
responding to transplant beneﬁtmay be slightly higher in patients
with PVT than in patients without thrombosis (MELD score of 13
vs. 11, respectively) [47]. The difference is likely to be due to
higher morbidity and mortality in those with thrombosis. How-
ever, it must be noted that there is no agreement onwhich thresh-
old MELD score value clearly identiﬁes patients who derive a
survival beneﬁt from transplantation in general [47,71]. In addi-
tion, this low threshold value (MELD score of 13) is not even com-
patible with listing for transplantation in many countries where
the scarcity of organs leads to transplant the sickest patients
[47]. Practically, such a low value may be unrealistic.Post-transplant rethrombosis, anticoagulation, and screening
Rethrombosis is a potential complication in patients with pre-
transplant PVT. Early rethrombosis generally results in graft loss
with the need for emergency re-transplantation (if possible)
[72]. There are few data on the impact of delayed PVT post-
transplantation. Experience shows that delayed PVT does not
necessarily lead to graft failure. The main consequences are
related to portal hypertension.
In theory, long term anticoagulation could help reduce the risk
of rethrombosis. For instance, patientswithmyeloproliferative dis-
orders and Budd–Chiari syndrome as the indication for transplan-2 vol. 57 j 203–212 209
Key Points 
• Portal vein thrombosis, either partial or complete, 
is found in between 5 to 25% of cirrhotic patients 
undergoing liver transplantation. During the transplant 
procedure, a substantial proportion of cirrhotic patients 
are found to have previously unrecognized portal vein 
thrombosis despite detailed imaging at evaluation
• In cirrhotic patients, the increase in intrahepatic vascular 
to be a predisposing factor for portal vein thrombosis. 
However, whether reduced portal blood flow is the major
resistance and decreased portal blood flow is likely
cause or is a cofactor needs to be further addressed
• The objective in the management of portal vein 
thrombosis pre-transplantation is to preserve or 
restore portal flow so that anatomical end-to-end portal
anastomomosis can be performed
• Anticoagulation (low molecular weight heparin [LMWH] 
or vitamin K antagonists [VKA]) and TIPS are two 
options to achieve portal vein patency and/or prevent 
the extension of the thrombus during waiting time. 
VKA allow complete recanalization in about 40 to 75% 
of patients with partial thrombosis without increasing 
the risk of bleeding during waiting time. LMWH is an 
Anticoagulation seems to be less effective in patients 
alternative with comparable safety and efficacy profile.
with complete thrombosis. However, more data is 
needed
• The MELD score is not valid in patients receiving VKA 
as these agents artificially increase INR.The MELD 
score would overestimate mortality risk and would over-
prioritize in patients receiving VKA
• TIPS is feasible in 75% to 100% of patients with portal 
vein thrombosis. However, in patients with advanced 
cirrhosis (MELD score over 18), TIPS may have an 
increased risk of further deteriorating liver function and 
of increasing mortality
• In the perspective of transplantation, TIPS should not be 
inserted distally into the portal vein, close to the terminal 
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tation are generally given long termanticoagulation in order to pre-
vent recurrence [73,74]. However, existing data suggest that in con-
trast to the hepatic vein thrombosis, pre-transplant PVT does not
justify long term anticoagulation. Firstly, in the largest series of cir-
rhotic patients with PVT undergoing transplantation, long term
VKA were not considered [5,6,8,9]. Secondly, even in the absence
of long term VKA, the rate of rethrombosis in patients who had
end-to-end portal anastomosis was very low (less than 5%)
[5,6,8,9]. Finally, as discussed above, PVT in cirrhotic patients is
more likely to be due to hemodynamic changes (decreased portal
ﬂow) than to coagulation disorders. In addition, inherited coagula-
tion disorders, if present, are likely to be cured by liver transplanta-
tion as the genome of the allograft turns to be that of the donor. If
adequate portal ﬂow to the allograft is restored and the anastomo-
sis is anatomical, the risk of rethrombosis seems to be low.
In patientswith extensive thrombosis andnon-anatomical proce-
dure (Table 5) such as caval transposition, the rate of rethrombosis is
higher [58,59].Whether the high rate of rethrombosis is related to an
underlying prothrombotic state or to complex anastomoses is
unclear. Early post-operative anticoagulation should be recom-
mended. The place of long term anticoagulation in this subgroup still
has to be determined.
Antiplatelet prophylaxis aiming at preventing hepatic artery
thrombosis and other cardiovascular complications is frequently
used after liver transplantation [75]. The effect of low dose aspirin
on the occurrence of venous thrombosis is contrasting. Some stud-
ies have shown that a short course of aspirin may reduce signiﬁ-
cantly the occurrence of venous thromboembolism in high risk
patients [76,77]. However, evidence that long term aspirin lowers
venous thromboembolism in low risk patients is lacking [78]. There
are no data in liver transplant recipients with a history of PVT.
Overall, in patients with anatomical portal anastomosis and ade-
quate portal ﬂow, a short course of heparin or fractionated heparin
may be recommended within the ﬁrst post-operative days to mini-
mize the risk of early rethrombosis. However, no data support the
use of long term anticoagulation. Patients with documented pro-
thrombotic state should receive long term anticoagulation provided
the prothrombotic state has not been reversed by transplantation.
Lifelong VKA remains the ﬁrst option. In patients with renoportal
anastomosis or caval transposition, the high rate of rethrombosis
argues for prolonged anticoagulation with VKA, even in the absence
of prothrombotic state.portion of the superior mesenteric vein or into the 
inferior vena cava. Misplacement may preclude portal 
anastomosis
• In patients with diffuse thrombosis, alternative non- 
anatomical techniques include renoportal anastomosis 
or caval hemitransposition. These techniques may not 
reverse portal hypertension
• There is no evidence that portal vein thrombosis per se 
increases waiting list mortality, independent of the MELD 
score. However, portal vein thrombosis is associated 
with increased post-transplant mortality and morbidity, 
especially when thrombosis is complete and extensive
• Anticoagulation in the early post-transplant course is 
term anticoagulation is not justified in patients with pre-
recommended to prevent rethrombosis. However, long 
transplant portal vein thrombosis provided anatomical 
end-to-end portal anastomosis can be performed and 
there is no underlying persistent prothrombotic state Conclusions
Decreased coagulation factors and low platelet count are not
protective against PVT in cirrhosis. Portal hypertension and
low portal ﬂow are the main factors leading to PVT. PVT is
rarely a deﬁnitive contraindication for transplantation. However,
it is a source of technical difﬁculties with increased morbidity
and mortality. Too many patients are still found with previously
unrecognized thrombosis at the time of transplantation empha-
sizing the need for more accurate screening. The main objective
in the management of patients with PVT is to allow conven-
tional end-to-end portal anastomosis with a physiological portal
ﬂow to the allograft. Anticoagulation and TIPS are the main
options to achieve these goals. When both are feasible, there
is no evidence that one option is deﬁnitely superior to the other.
However, even when technically feasible, TIPS may be contrain-
dicated in patients with severe impairment in liver function,210 Journal of Hepatology 2012 vol. 57 j 203–212
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which is common in candidates for transplantation. Anticoagu-
lation may consist in LMWH or VKA. The management of VKA
in patients with a marked baseline decrease in coagulation fac-
tors may be difﬁcult. Novel agents that do not require labora-
tory monitoring may be attractive in this context. Efforts
should be made to better identify patients with cirrhosis at high
risk for developing portal vein thrombosis, as prophylactic mea-
sures may be justiﬁed.Conﬂict of interest
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